ADJUVANT-CTONG 1104: Final OS Analysis of Phase III Study of Adjuvant Gefitinib vs Chemotherapy in Chinese Patients With Resected EGFR-Mutated NSCLC

May 29-31, 2020; Online at meetings.asco.org/am
At a median follow-up of 80 months, adjuvant gefitinib significantly improved DFS but not OS vs vinorelbine/cisplatin in Chinese patients with completely resected stage IIA-IIIA (N1-N2) EGFR-mutated NSCLC.
Format: Microsoft PowerPoint (.ppt)
File Size: 284 KB
Released: June 9, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
AstraZeneca
Daiichi Sankyo, Inc.
Ipsen Pharma
Jazz Pharmaceuticals, Inc.
Merck Sharp & Dohme Corp

Related Content

Karen L. Reckamp, MD, MS Released: August 14, 2020

CCO downloadable PDF: Key insights on biomarker testing and selecting targeted therapy for patients with advanced NSCLC

Released: August 10, 2020

CCO downloadable PDF: Highlights on current/evolving biomarkers for immune checkpoint inhibitor–based therapies in advanced NSCLC

Leora Horn, MD, MSc, FRCPC Edward S. Kim, MD, FACP Released: August 10, 2020

From Clinical Care Options (CCO), download this PDF summarizing HER2, HER3, and TROP2 testing and targeted therapeutics

Mark D. Pegram, MD Michael F. Press, MD, PhD Released: July 30, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?